DrugPatentWatch Database Preview
FABIOR Drug Profile
» See Plans and Pricing
Which patents cover Fabior, and when can generic versions of Fabior launch?
Fabior is a drug marketed by Mayne Pharma and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-four patent family members in eighteen countries.
The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fabior
A generic version of FABIOR was approved as tazarotene by TARO PHARMS on April 3rd, 2017.
Summary for FABIOR
| International Patents: | 24 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 112 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,342 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for FABIOR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FABIOR |
| What excipients (inactive ingredients) are in FABIOR? | FABIOR excipients list |
| DailyMed Link: | FABIOR at DailyMed |
Recent Clinical Trials for FABIOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Actavis Inc. | Phase 3 |
Pharmacology for FABIOR
| Drug Class | Retinoid |
US Patents and Regulatory Information for FABIOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | FABIOR | tazarotene | AEROSOL, FOAM;TOPICAL | 202428-001 | May 11, 2012 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| Mayne Pharma | FABIOR | tazarotene | AEROSOL, FOAM;TOPICAL | 202428-001 | May 11, 2012 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| Mayne Pharma | FABIOR | tazarotene | AEROSOL, FOAM;TOPICAL | 202428-001 | May 11, 2012 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FABIOR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010096868 | Get Started for $10 |
| Japan | 2016040291 | Get Started for $10 |
| Spain | 2696989 | Get Started for $10 |
| Chile | 2011002053 | Get Started for $10 |
| Poland | 2400951 | Get Started for $10 |
| Japan | 6182191 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for FABIOR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0284288 | SPC/GB98/002 | United Kingdom | Get Started for $10 | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 |
| 0284288 | 12/1998 | Austria | Get Started for $10 | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203 |
| 0031058 | 98C0008 | Belgium | Get Started for $10 | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
